This body of literature establishes the cell surface expression of PD-1/PD-L1 as a critical determinant for the identification of non-Hodgkin lymphoma patients eligible for immune checkpoint blockade therapies. This evidence concerns the gene PDCD1 and non-Hodgkin lymphoma.